Note sull'episodio
Joining the podcast today is Mark Muzzin, Managing Director of Nexsen Ltd (ASX: NXN). Mark speaks about how Nexsen is building next-generation rapid diagnostics, the company’s strategic direction, the development of its sensor platform, and the clinical and commercial pathways ahead.
1. Introduction to Company
“Mark, to begin, can you give us a clear introduction to Nexsen — what the company does, the problem it is solving in healthcare, and how its diagnostic platform stands apart?”
2. Strategy
“What is Nexsen’s overarching strategy for advancing its sensor technology from development to clinical adoption and ultimately commercial rollout?”
3. Flagship Programs / Lead Assays
“Can you walk us through Nexsen’s lead diagnostic programs — including the rapid Group B Strep test — and explain why these clinical indications were prioritised?”
4. Market Dynamics
“How do you view the current market dynamics in point-of-care and near-patient diagnostics, and what shifts in healthcare delivery are creating opportunities for Nexsen?”
5. Growth Opportunity
“Where do you see the strongest growth opportunities for Nexsen — whether in maternal health, infectious disease testing, chronic condition monitoring, or international healthcare markets?”
6. Financial Position
“Can you outline Nexsen’s financial footing and how the company plans to resource its clinical validation, regulatory activities and future commercialisation?”
7. Industry Collaboration
“What role do collaborations with universities, hospitals, research institutes and industry partners play in Nexsen’s development pathway, and what value do they bring?”
8. Upcoming Milestones
“What are the key scientific, clinical or regulatory milestones the market should look for from Nexsen over the next twelve months?”
9. Vision of Success
“Looking ahead, what does success look like for Nexsen — in terms of technology adoption, clinical impact, product availability and global footprint?”